What it is:Immunization practice is the whole workflow around giving a vaccine safely, not just the needle stick. It's screening the patient, picking the right product and site, handling a fragile biologic correctly, documenting it so it counts, and being ready if something goes wrong in the next fifteen minutes.
The core problem:Vaccines are biologics, not simple small-molecule drugs. They have to be stored within a narrow temperature window, they interact with the immune system in ways that depend on whether they're live or not, and a mistake (wrong site, blown cold chain, missed contraindication) either wastes an expensive dose or hurts a patient. On top of the clinical piece, your legal authority to even give the shot depends on the state you're standing in.
What you do about it:Screen every patient with the same short list of questions every time, know the difference between a true contraindication and a myth, respect the cold chain like it's insulin, and always know where your epinephrine is before you uncap the needle.
Almost everything in this topic branches off one fact: whether the vaccine is live or not.Live vaccines need a working immune system to be safe (so they're out for pregnancy and significant immunosuppression) and they compete with each other if given too close together (so there's a spacing rule). Inactivated vaccines can't cause the infection they prevent and don't have that interference problem, so almost none of the "wait X weeks" rules apply to them. Every time you're unsure about a timing or eligibility question, ask "live or not" first.
Every state grants pharmacists vaccine authority differently, and the specifics (which vaccines, what ages, whether a prescription is needed) are governed at the state board level, not federally. Oregon is a useful case study because it runs one of the more developed frameworks in the country, and it's the one you'll actually practice under.
| Pathway | Who does the clinical work | Example |
|---|---|---|
| Formulary | Pharmacist prescribes/dispenses to treat a condition already diagnosedby another qualified prescriber | Continuing a stable chronic med |
| Protocol | Pharmacist is the primary clinician: independent assessment, prescribing, and care plan, no outside diagnosis needed | Oregon's Vaccine Protocols |
| Standing Order | Issued by the state (e.g. the Oregon Health Authority) under a designated physician, used to strip away administrative friction for a public-health priority | Naloxone; OTC contraception billing |
In Oregon, vaccination is delivered as a Protocolunder the Public Health and Pharmacy Formulary Advisory Committee (PHPFAC), a multidisciplinary board (physicians, advanced practice RNs, and pharmacists) that recommends formulary and protocol content to the Oregon Board of Pharmacy for adoption by rule. That rules-based structure exists specifically so that pharmacist scope can expand without needing a new bill through the legislature every time.
| Protocol | Covers |
|---|---|
| Vaccination Protocol, Adults 18+ | Standard adult immunization schedule |
| Vaccination Protocol, Ages 7-17 | Adolescent schedule, with the age floor below |
| Vaccination Protocol for Managing Adverse Reactions | What you do in the fifteen minutes after the shot if something goes wrong |
Other than influenza vaccines, an Oregon-licensed pharmacist may only prescribe and administer vaccines to patients 7 years of age and older(ORS 689.645). Flu is carved out with a lower age floor. If a parent brings in a 4-year-old for a routine catch-up vaccine, that's outside your protocol authority even though you could give that same 4-year-old a flu shot.
COVID-19, influenza, and RSV vaccines run on a separate, faster-moving trackoutside the standard PHPFAC rulemaking process, because ACIP recommendations for these three shift frequently (annual reformulation, evolving risk-group guidance) and a full board rulemaking cycle is too slow to keep pace. That speed cuts both ways: in August 2025, the FDA narrowed approval of an updated COVID-19 vaccine to adults 65 and older plus people 6 months to 64 with underlying conditions before ACIP had issued a matching recommendation, and CDC simultaneously shifted healthy children and pregnant patients to shared clinical decision-making. Because pharmacist protocol authority is built to follow ACIP, that guidance gap translated directly into real friction: pharmacies unsure whether to stock the vaccine, patients being asked for prescriptions or risk attestations that weren't previously required, and confused front-line conversations at the counter.
This is why "check ACIP" isn't just an academic instruction, it's the thing your actual prescribing authority is chained to. When ACIP and FDA approval are out of sync, your protocol can be ambiguous even though the vaccine is sitting in your fridge. Know where to check your specific state's current protocol language before you assume you can give a shot, especially for COVID-19, flu, and RSV each fall.
You don't need a full immunology course to practice safely, but you need enough of the mechanism to understand why the timing and eligibility rules exist instead of memorizing them as arbitrary trivia.
| Active immunity | Passive immunity | |
|---|---|---|
| How it's created | Your own immune system responds to an antigen (from infection or vaccination) | Preformed antibodies are given directly (immunoglobulin, monoclonal antibody, or maternal antibody crossing the placenta) |
| Onset | Delayed, typically ~2 weeks to reach a protective antibody titer | Immediate |
| Duration | Long, often years to lifetime, because memory B and T cells form | Short, weeks to a few months, because no memory cells are created |
| Example | MMR vaccine, natural infection | RSV monoclonal antibody in infants, tetanus immune globulin, maternal antibodies in a newborn |
A vaccine given the day before, or even several days before, an exposure often will not protect against that specific exposure, because the adaptive immune response hasn't had time to build a protective antibody titer yet. That's why the flu shot needs to go in weeks before flu season peaks, not the week symptoms start showing up in your building.
When enough of a population is immune, a pathogen can't find enough susceptible hosts to sustain a chain of transmission, which indirectly protects people who can't be vaccinated (infants too young, immunocompromised patients, true allergy to a vaccine component). The coverage threshold needed scales with how contagious the disease is. Measles, with a basic reproduction number in the 12-18 range, needs roughly 95% community coverage to stay suppressed, which is why even small drops in MMR uptake show up as real outbreaks. Less contagious diseases need lower coverage to hit that threshold.
The platform a vaccine is built on determines almost every practical rule you'll apply to it: who can't get it, whether it competes with other vaccines, and how it's stored.
| Live attenuated | ||
| Platform | Examples | Why it behaves the way it does |
|---|---|---|
| Weakened, still-replicating organism | MMR, varicella, zoster (Zostavax, largely phased out), rotavirus, intranasal influenza (LAIV), yellow fever | Produces a robust, long-lasting immune response because it mimics natural infection, but the organism can still replicate, so it's contraindicated in pregnancy and significant immunosuppression |
| Inactivated (whole-cell/killed) | ||
| Platform | Examples | Why it behaves the way it does |
| Killed whole organism, cannot replicate | Inactivated polio (IPV), hepatitis A, injectable influenza (standard-dose) | Safe in pregnancy and immunosuppression since there's no live organism, but usually needs multiple doses or boosters since the immune response is weaker than natural infection |
| Subunit, recombinant, conjugate, polysaccharide | ||
| Platform | Examples | Why it behaves the way it does |
| Just the piece of the organism the immune system needs to recognize | Hepatitis B (recombinant), HPV (recombinant), Shingrix (recombinant subunit + adjuvant), pneumococcal conjugate (PCV) vs. plain polysaccharide (PPSV23), meningococcal conjugate (MenACWY) vs. serogroup B (MenB) | No live component, safe broadly. Conjugating a polysaccharide to a protein carrier (like PCV vs. PPSV23) converts a weak, T-cell-independent response into a strong, memory-forming one, which is why conjugate vaccines work in infants and plain polysaccharide vaccines don't |
| Toxoid | ||
| Platform | Examples | Why it behaves the way it does |
| Inactivated bacterial toxin | Diphtheria and tetanus toxoids (the "T" in Tdap/Td) | You're vaccinating against the toxin's damage, not the bacterium itself, so protection is about neutralizing antibody levels and needs periodic boosting |
| mRNA and viral vector | ||
| Platform | Examples | Why it behaves the way it does |
| Genetic instructions delivered to make the antigen inside the patient's own cells | mRNA COVID-19 vaccines (Pfizer, Moderna); viral vector platforms (used historically for some COVID-19 and Ebola vaccines) | Not a live pathogen and cannot cause the disease, safe in pregnancy and most immunosuppression, but formulation-specific ultra-cold storage requirements are the tradeoff |
Two injectablelive vaccines given on different days (not the same visit) need to be separated by at least 4 weeks. The mechanism is interferon: the first live vaccine triggers an innate interferon response that can suppress replication of a second live vaccine given too soon after, blunting the immune response to the second one. Giving both on the same day sidesteps the problem entirely, since the interference only shows up when they're staggered too closely.
Inactivated vaccines don't have this problem at all.There's no minimum interval required between two inactivated vaccines, or between an inactivated vaccine and a live one, regardless of timing. This is one of the most commonly missed distractors: students assume "space out vaccines" is a universal rule, when it's actually a live-vaccine-specific one.
Antibody-containing products (immunoglobulin, blood products) and live vaccines also interact.Circulating antibody from a recent immunoglobulin dose can neutralize a live vaccine's antigen before it can trigger a real immune response. Depending on the product and dose, MMR and varicella may need to be delayed anywhere from about 3 to 11 months after an antibody product. If the live vaccine is given first, a subsequent antibody product should generally wait at least 2 weeks, otherwise the vaccine response may need to be reassessed.
Every patient, every visit, gets the same short screen before the needle comes out. The goal is catching the small number of real contraindications without turning away patients over things that were never actually a problem.
| Contraindication | Applies to |
|---|---|
| Anaphylaxis to a previous dose, or to a vaccine component | Any vaccine containing that component, permanently |
| Pregnancy | Live vaccines only |
| Significant immunosuppression | Live vaccines, with some nuance by condition and degree |
| Encephalopathy within 7 days of a pertussis-containing dose, not attributable to another cause | Further pertussis-containing vaccines (switch to DT, which drops the pertussis component) |
| History of intussusception, or SCID | Rotavirus vaccine |
| Precaution | What to do |
|---|---|
| Moderate-to-severe acute illness, with or without fever | Defer until the patient recovers |
| Guillain-Barré syndrome within 6 weeks of a prior flu vaccine | Individualize; usually still proceed, discuss risk |
| Thrombocytopenia or thrombocytopenic purpura after a prior dose (e.g., after MMR) | Individualize; weigh disease risk against recurrence risk |
Mild illness or low-grade fever, current antibiotics, breastfeeding, preterm birth, a family history of an adverse reaction, or a mild local reaction to a previous doseare not reasons to withhold a vaccine. The single biggest one to unlearn: egg allergy is no longer a special precaution for influenza vaccine, at any severity.Current guidance says all flu vaccine formulations can be given to egg-allergic patients in any vaccine-administering setting, with no extended observation required specifically for the egg allergy.
Federal law (the National Childhood Vaccine Injury Act) requires you to give the patient a Vaccine Information Statement (VIS)before administering most routine vaccines, and to document which edition/publication date you gave. Always use the current version, an outdated VIS is a documentation gap even if the shot itself was appropriate.
This isn't the full pediatric catch-up schedule, it's the adult core you'll be asked about constantly at the counter and on exams.
| Routine, everyone | ||
| Vaccine | Who / when | Detail worth knowing |
|---|---|---|
| Influenza | Annually, everyone ≥6 months | Reformulated yearly to match circulating strains; egg allergy is not a barrier |
| Tdap / Td | Tdap once, then a Td or Tdap booster every 10 years | Tdap in every single pregnancy, ideally early in the 27-36 week window to maximize transplacental pertussis antibody transfer to the newborn |
| COVID-19 | Updated annually per current formulation | Runs on the fast-moving "board excluded" track, check current age/risk-group guidance each season |
| Age or risk-based | ||
| Vaccine | Who / when | Detail worth knowing |
| Zoster (Shingrix) | 2 doses, 2-6 months apart, age ≥50 (or ≥19 with immunocompromise) | Recombinant subunit, not live, so it's an option for the immunocompromised patients Zostavax excluded |
| Pneumococcal | Age ≥65, or younger with risk factors | PCV20 alone, orPCV15 followed by PPSV23 about a year later, current guidance leans toward the single-product PCV20 pathway for simplicity |
| Hepatitis B | Now a universal recommendation for adults 19-59, risk-based ≥60 | Recombinant, 2- or 3-dose series depending on product |
| HPV | Routine through age 26; shared clinical decision-making 27-45 | Ideally given before sexual debut, but not restricted to that |
| MMR | Adults born ≥1957 without evidence of immunity get 1-2 doses; healthcare workers need 2 | Live, avoid in pregnancy and immunosuppression |
| Varicella | 2 doses if no evidence of immunity | Live, same pregnancy/immunosuppression caveats as MMR |
| Meningococcal (ACWY / B) | Risk groups, including many college students in congregate housing | MenB is a separate shared-decision-making conversation from MenACWY, not a substitute for it |
| RSV | Single dose, age ≥75, or 60-74 with risk factors | Shared clinical decision-making, not a blanket recommendation at 60 |
Site selection and needle sizing aren't arbitrary either, they're chosen to reliably land the vaccine in the tissue it needs to be in without hitting nerve or bone.
Give each vaccine in a different anatomic sitewhen possible (opposite deltoids, or deltoid plus thigh). If you have to use the same limb, separate injection sites by at least 1 inch. There's no clinical downside to giving several vaccines the same day, the "too many shots at once" concern is not supported by data.
Use the smallest gauge needle that will work, apply firm pressure without rubbingfor at least 2 minutes after an IM injection, and consider timing the vaccine right after a scheduled clotting factor dose for patients on factor replacement.
A vaccine that's been mishandled isn't automatically dangerous, but it can be silently ineffective, and you'd have no way to tell just by looking at the vial.
| Storage condition | Range | Applies to |
|---|---|---|
| Refrigerated | 36-46°F (2-8°C) | Most inactivated vaccines, and most current MMR/varicella formulations |
| Frozen | Product-specific, historically down to -58 to +5°F | Some older varicella-containing products; increasingly rare as products are reformulated for refrigerator stability |
| Ultra-cold / frozen, product-specific | Varies by manufacturer and formulation | mRNA COVID-19 vaccines; once thawed or punctured, multidose vials have a defined beyond-use window that does not reset |
Do not automatically discard vaccine that's been out of range. Move it to correct storage immediately, label it "do not use" and quarantine it, then documentthe minimum/maximum temperature reached and how long the excursion lasted. Contact the manufacturer or your state/local health department for a viability determination before deciding to use or discard, guessing wrong either way either wastes usable vaccine or gives a dose that may not protect the patient.
Vaccines for Children (VFC)is the federal program supplying ACIP-recommended vaccines at no cost to enrolled providers, for patients through age 18 who are uninsured, Medicaid-eligible, American Indian/Alaska Native, or underinsured (the underinsured category typically only applies at an FQHC, rural health clinic, or under a deputization arrangement). Knowing whether a pediatric patient qualifies is part of making the visit actually happen instead of turning a family away over cost.
| Safe and recommended | Avoid |
|---|---|
| Inactivated, recombinant, toxoid, and mRNA vaccines, including flu (any trimester), Tdap (every pregnancy), and COVID-19 | All live vaccines: MMR, varicella, LAIV nasal flu, zoster |
If a live vaccine is inadvertently given during pregnancy, or pregnancy occurs within 4 weeks of one, counsel that surveillance data have not shown harm, but the standing recommendation is still to avoid it out of caution.
Live vaccines are generally avoided (replicating organism risk), while inactivated vaccines remain the right call but may produce a blunted antibody response depending on the degree of immunosuppression, meaning timing relative to chemotherapy or immunosuppressive therapy matters when it can be planned. Cocooning, making sure household contacts are fully up to date on their own vaccines, is a real protective strategy for a patient who can't safely receive certain vaccines themselves.
Vaccinate on the same chronological-age schedule as full-term infants, not an adjusted age, and do not reduce the dose for low birth weight.
This is the part of immunization practice with zero margin for improvisation. Every site giving vaccines needs epinephrine immediately available and a clear protocol before the first patient of the day walks in.
| Vasovagal syncope | Anaphylaxis | |
|---|---|---|
| Onset | Usually within 15 minutes | Usually within minutes, can be immediate |
| Presentation | Pale, diaphoretic, bradycardic, feels faint | Skin (urticaria, flushing, swelling), respiratory (wheeze, stridor, throat tightness), and/or cardiovascular (hypotension, tachycardia) involvement |
| What resolves it | Lying the patient flat, legs elevated | Immediate IM epinephrine into the anterolateral thigh, then call 911 |
Every patient gets a minimum 15-minute observation period after vaccination, extended to 30 minutes for anyone with a history of syncope or a significant allergy history.This isn't a courtesy, it's the window where the overwhelming majority of immediate reactions declare themselves. Don't let a patient walk out the door early because the line is long.
| What | When | Watching for |
|---|---|---|
| Observation period | Immediately post-injection | Syncope vs. anaphylaxis, 15 min standard / 30 min elevated risk |
| Documentation(vaccine, manufacturer, lot, site/route, VIS edition date, vaccinator) | Every dose, every patient | Complete enough to trace a lot in the event of a recall or an adverse event cluster |
| State immunization registry(Oregon: ALERT IIS) | Every dose | Duplicate or missed doses across different providers over the patient's lifetime |
| VAERS reporting | Any event on the Reportable Events Table, or anything listed by the manufacturer as a contraindication to future doses; voluntary for any other clinically significant event | Signal detection across the population, not a determination of causation for any single report |
| PCP notification | Within 5 business days of prescribing under a formulary or protocol | Continuity of care, so the vaccine ends up in the patient's full record, not just yours |
VAERS(Vaccine Adverse Event Reporting System, co-run by CDC and FDA) is a passive surveillance system, anyone can report, reporting is not an admission that the vaccine caused the event. The National Vaccine Injury Compensation Program (VICP)is a completely separate, no-fault system that compensates patients found to have been injured by a covered vaccine, funded by an excise tax on the vaccines themselves. Don't conflate reporting a possible reaction with a legal finding of injury, they're different systems doing different jobs.